CACA webinar: Enhanced Sensitivity for Large and Small Molecule Analysis Using a New 1.5mm ID Column
Speaker: Peter Pellegrinelli, M.S. Application Specialist Advanced Materials Technology, Inc.
When: Wed, Aug 17, 2022 9:00 AM - 10:00 AM PDT
Registration link: https://register.gotowebinar.com/register/5706044659869535244
Chromatographers continue to explore alternate avenues to improve their chromatography separations. These avenues can encompass different parameters including connection tubing, instrumentation configuration, column choice, amongst others. If the method requirements permit freedom for change, adjusting method parameters or exchanging the column are simple changes. It is well known that by switching from larger ID columns to a smaller ID can reduce overall solvent consumption and improve sensitivity. Previously, in order to improve the method sensitivity using a 2.1 mm ID, a specialized micro or nano flow LC system using capillary columns was used. However, this can be an expensive venture to undertake to improve one’s chromatography system performance from a routine operational and maintenance standpoint.
In this webinar a new 1.5mm ID column technology will be discussed. Skipping the expense of a specialized system and gain improvements in both sensitivity and reduced solvent consumption with a commercial UHPLC system will also be presented. This new column dimension shows an increase in sensitivity through both UV and MS applications. With greater response and higher ionization efficiencies problematic separations can be overcome. Advantages to the proteomic and peptide mapping applications will be shown along with some small molecule application examples.
Key Learning Objectives:
• How a new 1.5 mm ID column delivers an increase in sensitivity for UHPLC and LCMS separations
• Ability to implement and achieve green initiatives with new column technology
• Getting more performance from your UHPLC system
Who Should Attend:
• Chromatographers developing methods for large and small molecule separations
• UHPLC users interested in increasing sensitivity
• Researchers looking to reduce solvent consumption
CACA Webinar: Mitigating Analyte Interactions with Metal Surfaces in UHPLC for Pharmaceutical Applications
Speakers:
• Catharine Layton, Principal Scientist, Scientific Operations, Waters
• Martin Gilar, Ph. D., Scientific Fellow, Separations R&D, Waters Corporation
When: Wed, Jul 20, 2022 9:00 AM - 10:00 AM PDT
Registrtion link: https://register.gotowebinar.com/register/496557467017393934
Event Overview:
Non-specific binding of analytes to material surfaces is an inherent characteristic of conventional chromatographic columns and systems. This phenomenon leads to reduced sensitivity and sometimes poor peak shape of acidic molecules. In this webinar we will present a new, novel hybrid surface technology that provides a solution without the need for strong mobile phase additives, chelators, or lengthy passivation protocols. The chromatographic benefits provided when using columns and systems equipped with the MaxPeak™ High Performance Surfaces (HPS) technology will be demonstrated with antivirals, NSAIDs, cancer growth inhibitors, oligonucleotides, peptides, and glycans.
Key Learning Objectives:
• Understand how metal-analyte interactions can negatively impact chromatographic performance.
• Learn how to mitigate metal-analyte interactions with the use of a novel surface technology.
• Explore applications: antivirals, NSAIDs, cancer growth inhibitors, oligonucleotides, peptides and glycans.
Who Should Attend:
• Scientists who develop and/or manage UHPLC and HPLC methods in pharmaceutical laboratories.
• Lab managers leading teams involved with the analysis of small and large molecules.
CACA Webinar: Analysis of Genotoxic Nitrosamines in Active Pharmaceutical Ingredients
Speakers: Tony Edge, Ph.D., Site Director (Product R&D), Avantor Hichrom
When: Wed, Nov 3, 2021 9:00 AM - 10:00 AM PDT
Registation link: https://register.gotowebinar.com/register/2746521090651166731
Event Overview: In the summer of 2018, the pharmaceutical landscape for the manufacture of small molecules has changed forever with the discovery of a genotoxic compound called N-nitrosodimethylamine (NDMA) in a batch of Valsartan manufactured by Zhejiang Huahai Pharmaceutical in China. Valsartan is a prescription only drug to treat high blood pressure and heart failure, which is a selective angiotensin II receptor blocker (ARB) used to dilates blood vessels. In routine analysis, the QC chemists found that there were approaching 60 ppm of NDMA, which is high enough to cause one extra case of cancer in 500 patients. On 5th July of 2018, the European Medical Agency (EMA) gave notice to recall selected batches of Valsartan with immediate effect. Since 2018, NDMA and other nitrosamines have been detected at alerted levels in a range of different pharmaceuticals.
This webinar will look at the chronological development of the story and how nitrosamines have caused the pharmaceutical industry to re-evaluate their manufacturing procedures. It will look at the synthetic pathways that can generate these genotoxins and the regulatory landscape that has evolved as a consequence of the initial findings. We will then discuss the development of a series of applications that will allow for the determination of nitrosamines that have been identified as genotoxins by the US Food and Drug Administration (FDA) to monitor, initially showing how to perform a separation of these compounds from the active pharmaceutical ingredient (API) and then looking at how mass spectrometry can be applied to the analysis to ensure that the required detection limits can be reached.
Key learning Objectives:
• Learn the importance of testing for NDMA concentrations in pharmaceuticals
• Understand the regulatory landscape that has evolved to deal with this range of genotoxins such as nitrosamines impurities
• Review examples of nitrosamine analysis
CACA webinar: Utilizing RPLC and HILIC Separation Modes for Improved mAb Characterization
Speaker: Stephanie A. Schuster, Senior Technical Support Scientist, Advanced Materials Technology, Inc.
When: Wed, Sep 22, 2021 9:00 AM - 10:00 AM PDT
Registration link: https://register.gotowebinar.com/register/2175932829156698636
About the Speaker: Dr. Schuster earned her B.A. at La Salle University, and her Ph.D. under the guidance of Prof. Joe P. Foley at Drexel University. After graduation, Stephanie spent nine months at Atlantic Diagnostic Laboratories, a combined clinical and forensic testing laboratory. She joined Advanced Materials Technology, Inc. (AMT) located in Wilmington, DE in June 2009 as a research scientist working with Dr. Jack Kirkland, providing contributions to the commercial development of products designed specifically for the separation of peptides and proteins. Most recently, as part of the Technical Support team at AMT, Stephanie has been providing customers support in optimizing and trouble-shooting their applications. Stephanie has several peer-reviewed articles and is a member of the Chromatography Forum of the Delaware Valley (CFDV) and the American Society of Mass Spectrometry (ASMS).
Abstract: Monoclonal antibodies (mAbs) continue to be among the top selling pharmaceuticals because they are such effective therapeutics. Not only are mAbs used for disease treatment, but they are also used for research and diagnostic purposes. Characterization of mAbs is a critical step in their development. Intact analysis may be completed by LC-UV or LC-MS methods using Fused-Core particle columns. Additionally, post-translational modifications (PTMs) of mAbs must be characterized and controlled. Many PTMs are polar by their nature, including glycosylation, deamidation, and oxidation. These types of polar modifications lend themselves to analysis via hydrophilic interaction liquid chromatography (HILIC) since they can be better resolved than with reversed-phase chromatography. Examples of glycosylation, deamidation, and oxidation of different mAbs will be demonstrated using LCMS under HILIC conditions.
CACA weibinar: Application of ion chromatography in pharmaceutical industry
Speaker: Yichen Wang, Specialist of Ion Chromatography, Product Manager of SHINE Ion Chromatography
When: Wed, Aug 25, 2021 9:00 AM - 10:00 AM PDT
Registration link: https://register.gotowebinar.com/register/7955049475103076098
Abstract: Ion chromatography (IC), a well-established form of liquid chromatography, uses ion-exchange resins to separate cations or anions. There are two types of IC, anion-exchange and cation-exchange. Equipped with different detectors, IC could be a powerful separation technique to address challenging analytical tasks. For example, IC can detect carbohydrate in dairy products using electrochemical detector. Recently, IC has been extensively used for purification and characterization of biopharmaceutical drugs such as monoclonal antibody (mAb) and adeno-associated virus (AAV). Trace analysis of elemental impurities with low detection limit can be achieved with combination of ICP-MS/MS. It is possible to detect hexavalent ions such as chromium at ppt levels in toys.
Due to its excellent sensitivity, selectivity, and fast speed, IC has proven to be a very useful technique for determination of both organic and inorganic ions (in particular non-metal ions) and applied in various fields such as food, environmental, material and pharmaceutical analyses. To explore the growing interest of IC in pharmaceutical industry, this seminar will start with a brief introduction of IC principle, operation, and instrumentation followed by its application in analysis of raw materials, intermediates, drug substance, excipients, and finished drug products based on pharmacopeia standards from different countries.
Key Learning Objectives:
• Brief introduction of IC Principle, operation and instrumentation
• Application of IC in pharmaceutical drug analysis
Who Should Attend:
• IC users and method developers in pharmaceutical, chemical, clinical, environmental, agrichemical, contract research organizations, universities, and governmental laboratories.
Page 1 of 2